Wednesday, July 8, 2026

pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX

Travere Therapeutics

Travere Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US HQ
2020 Founded
506 Employees
Public company Type
TVTX · NYSE Ticker
Company details
Status
Public
HQ
3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
Founded
2020
Employees
506
Programs
13
Drugs
9
Patents
1
Intelligence · Clinical Programs

Travere Therapeutics projects

13 ClinicalTrials.gov programs sponsored by Travere Therapeutics.

Travere Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 021FSGS16010

    Travere Therapeutics

    Focal segmental glomerulosclerosis (FSGS)

    phase 3 small molecule active

    1 trial
  2. 021IGAN17001

    Travere Therapeutics

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial
  3. Fosmetpantotenate

    Travere Therapeutics

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule terminated

    1 trial
  4. Pegtibatinase

    Travere Therapeutics

    Homocystinuria

    phase 3 small molecule active

    3 trials
  5. TVTX-TVT058-301

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial
  6. sparsentan

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    2 trials
  7. sparsentan

    Travere Therapeutics

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    3 trials
  8. RE-021 (Sparsentan)

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule completed

    1 trial
  9. RTRX-RE021-201

    Travere Therapeutics

    Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

    phase 2 small molecule active

    1 trial
  10. Sparsentan

    Travere Therapeutics

    ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial
  11. RE-021, sparsentan

    Travere Therapeutics

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  12. sparsentan

    Travere Therapeutics

    Proteinuric Renal Disease

    phase 1 small molecule active

    1 trial
  13. Sparsentan

    Travere Therapeutics

    Proteinuria

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Travere Therapeutics have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.